Validation of a New High-Throughput BD COR System Using the BD CTGCTV2 Assay

Prior research has established nucleic acid amplification tests as reliable tools for detecting sexually transmitted infections. However, validating new diagnostic platforms remains a challenge. It was already known that the BD MAX System performs well for detecting Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. That uncertainty drove the need to assess whether the BD COR System could deliver comparable results. No prior work had resolved whether the CTGCTV2 assay on the COR system would match the MAX system's performance. This gap motivated the study to evaluate precision and reproducibility of the new system. The study aimed to confirm whether the COR system could be reliably used in clinical settings. The researchers sought to ensure that the new system would not introduce variability in test results. This work addresses the need for robust diagnostic platforms in clinical microbiology.

The aim of this study was to evaluate the precision and reproducibility of the BD CTGCTV2 assay on the BD COR System. The researchers focused on comparing clinical performance of the assay on the COR system with its performance on the BD MAX System. The specific problem addressed was whether the new system could reliably detect Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. The motivation stemmed from the need to validate the COR system for clinical use. The study aimed to confirm that the COR system would produce consistent results across multiple days and sites. The researchers wanted to ensure that the new system would not compromise diagnostic accuracy. This work supports the adoption of the COR system in clinical laboratories. The study's findings aim to inform diagnostic workflow decisions.

The study used contrived panels of positive and negative urine and PreservCyt specimens to assess precision and reproducibility. Multiday and multisite studies were conducted to evaluate system performance. A total of 433 panel members were tested in the clinical comparison study. Each sample was tested three times on both the MAX and COR systems. Agreement between results was analyzed by target using statistical methods. Cycle threshold scores were compared using paired t-tests and Deming regression. The study design included both precision and reproducibility assessments. The researchers focused on detecting three specific pathogens in clinical specimens.

The CTGCTV2 assay on the COR system showed high reproducibility in multiday and multisite analyses. Positive percent agreement exceeded 95% for all three targets in the clinical comparison. Negative percent agreement also exceeded 95% for all three targets. The lower bounds of two-sided 95% confidence intervals were all above 90%. Cycle threshold scores from MAX and COR showed no systematic difference. Paired t-tests confirmed no significant mean difference between systems. Deming regression analysis supported equivalent performance between the systems. These results suggest the COR system performs as well as the MAX system for diagnostic testing.

The study found that the CTGCTV2 assay on the COR system performs equivalently to the MAX system. The authors propose that the COR system is suitable for clinical use based on these findings. The reproducibility of results was confirmed through multiday and multisite studies. Agreement between systems exceeded 95% for all three pathogens. No systematic differences were detected in cycle threshold scores. The researchers suggest that the COR system can be used with confidence in diagnostic settings. These findings support the validation of the new system for clinical microbiology. The authors emphasize the importance of reliable diagnostic platforms in clinical practice.